Author of the publication

Please choose a person to relate this publication to

To differ between persons with the same name, the academic degree and the title of an important publication will be displayed. You can also use the button next to the name to display some publications already assigned to the person.

 

Other publications of authors with the same name

Repurposing screen identifies novel candidates for broad-spectrum coronavirus antivirals and druggable host targets, , , , , , , , , and 12 other author(s). Antimicrob Agents Chemother, 68 (3): e0121023 (February 2024)Respiratory Syncytial Virus Two-Step Infection Screen Reveals Inhibitors of Early and Late Life Cycle Stages, , , , , , , , , and 9 other author(s). Antimicrob Agents Chemother, 66 (12): e0103222 (November 2022)Drug repurposing screen identifies lonafarnib as respiratory syncytial virus fusion protein inhibitor, , , , , , , , , and 22 other author(s). Nat Commun, 15 (1): 1173 (Feb 8, 2024)Thiamyxins: Structure and Biosynthesis of Myxobacterial RNA-Virus Inhibitors, , , , , , , , , and 2 other author(s). Angew Chem Int Ed Engl, 61 (52): e202212946 (October 2022)Persicamidines- Unprecedented Sesquarterpenoids with Potent Antiviral Bioactivity against Coronaviruses, , , , , , , , , and 3 other author(s). Angew Chem Int Ed Engl, 62 (6): e202214595 (November 2023)Impaired immune response mediated by prostaglandin E2 promotes severe COVID-19 disease, , , , , , , , , and 19 other author(s). PLOS ONE, 16 (8): 1-24 (August 2021)Filovirus antiviral activity of cationic amphiphilic drugs is associated with lipophilicity and ability to induce phospholipidosis, , , , , , , , and . Antimicrob Agents Chemother, (2020)